Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Agilent launches GenetiSure Dx Postnatal Assay for detection of anomalies

Agilent launches GenetiSure Dx Postnatal Assay for detection of anomalies

3rd March 2017

Agilent Technologies has announced the launch of the GenetiSure Dx Postnatal Assay, its first comparative genomic hybridisation assay for diagnostic use.

The test is designed for use on newborn infants and will enable clinical geneticists to detect genetic anomalies associated with developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features earlier and more accurately.

Based on Agilent's proprietary array for comparative genomic hybridisation, which provides data on copy number variations and absence of heterozygosity, the test is the result of an extensive clinical validation process.

By identifying a definitive genetic diagnosis, the assay allows care teams to change the focus of a medical investigation from finding the cause to administering appropriate medical care and family support as soon as possible.

Herman Verrelst, Agilent's vice-president and general manager of its genomic solutions and clinical applications divisions, said: "The GenetiSure Dx Postnatal Assay has been developed for cytogenetic laboratories, combining high-quality data with easy laboratory setup and streamlined protocols."

The test has received European CE Mark approval for in vitro diagnostic applications.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801833201-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.